KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accounts Payables: 2010-2025

Historic Accounts Payables for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $57.4 million.

  • Emergent BioSolutions' Accounts Payables fell 30.09% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 million, marking a year-over-year decrease of 30.09%. This contributed to the annual value of $60.9 million for FY2024, which is 45.72% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Accounts Payables stood at $57.4 million, which was down 9.89% from $63.7 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Accounts Payables peaked at $151.8 million during Q2 2021, and registered a low of $57.4 million during Q3 2025.
  • For the 3-year period, Emergent BioSolutions' Accounts Payables averaged around $88.7 million, with its median value being $95.9 million (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' Accounts Payables skyrocketed by 79.01% in 2021, and later crashed by 45.72% in 2024.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Accounts Payables stood at $128.9 million in 2021, then declined by 19.71% to $103.5 million in 2022, then increased by 8.41% to $112.2 million in 2023, then crashed by 45.72% to $60.9 million in 2024, then crashed by 30.09% to $57.4 million in 2025.
  • Its Accounts Payables stands at $57.4 million for Q3 2025, versus $63.7 million for Q2 2025 and $58.1 million for Q1 2025.